| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,653,000 |
| Market
Cap: |
2.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.187 - $0.187 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Boyd Steven |
10% Owner |
– – • |
2018-04-16 |
4 |
B |
$0.38 |
$435,731 |
D/D |
1,159,167 |
11,816,890 |
2.45 |
- |
|
| Boyd Steven |
10% Owner |
– – • |
2018-04-13 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
10,657,723 |
1.42 |
- |
|
| Boyd Steven |
10% Owner |
– – • |
2018-04-13 |
4 |
B |
$0.33 |
$2,466,649 |
D/D |
7,425,193 |
10,657,723 |
2.45 |
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-12-29 |
4 |
A |
$1.01 |
$12,479 |
D/D |
12,355 |
240,397 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2017-12-29 |
4 |
A |
$1.01 |
$6,789 |
D/D |
6,722 |
18,473 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2017-12-29 |
4 |
A |
$1.01 |
$11,982 |
D/D |
11,863 |
44,363 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2017-12-29 |
4 |
A |
$1.01 |
$12,479 |
D/D |
12,355 |
284,820 |
|
- |
|
| Garanzini Michael |
Chief Commercial Officer |
• – – |
2017-11-17 |
4 |
A |
$1.07 |
$16,050 |
D/D |
15,000 |
15,000 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-09-15 |
4 |
A |
$1.20 |
$10,800 |
D/D |
9,000 |
228,042 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-09-14 |
4 |
A |
$1.23 |
$11,070 |
I/I |
9,000 |
50,700 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-09-14 |
4 |
A |
$1.22 |
$1,464 |
D/D |
1,200 |
219,042 |
|
- |
|
| Romano Sarah |
Interim CFO |
• – – |
2017-08-15 |
4 |
B |
$1.00 |
$10,000 |
D/D |
10,000 |
32,500 |
2.74 |
- |
|
| From Stephen |
President and CEO |
• • – |
2017-08-10 |
4 |
B |
$1.03 |
$12,875 |
D/D |
12,500 |
272,465 |
2.81 |
- |
|
| From Stephen |
President and CEO |
• • – |
2017-06-14 |
4 |
B |
$0.00 |
$0 |
D/D |
60,000 |
259,965 |
2.73 |
- |
|
| Romano Sarah |
Interim CFO |
• – – |
2017-06-14 |
4 |
B |
$0.00 |
$0 |
D/D |
20,000 |
22,500 |
2.66 |
- |
|
| Chaney Paul G |
Director |
– • – |
2017-06-02 |
4 |
OE |
$0.65 |
$11,421 |
D/D |
17,570 |
41,229 |
|
- |
|
| Manzo Michael P. |
Vice President of Engineering |
• – – |
2017-05-15 |
4 |
OE |
$0.65 |
$4,735 |
D/D |
7,285 |
19,546 |
|
- |
|
| Ventech Capital Ii |
10% Owner |
– – • |
2017-03-13 |
4 |
S |
$2.80 |
$12,385 |
D/D |
(4,419) |
1,431,814 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-03-07 |
4 |
A |
$2.83 |
$24,621 |
D/D |
8,700 |
217,842 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-02-28 |
4 |
A |
$2.60 |
$108,420 |
I/I |
41,700 |
41,700 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-02-28 |
4 |
A |
$2.59 |
$140,378 |
D/D |
54,200 |
209,142 |
|
- |
|
| Goldberg Morton |
Director |
– • – |
2017-02-27 |
4 |
OE |
$1.70 |
$1,841 |
D/D |
1,083 |
18,360 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2017-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
11,751 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2017-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
199,965 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2017-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
154,942 |
|
- |
|
289 Records found
|
|
Page 10 of 12 |
|
|
